Table 3.

Number and proportion of patients with changes in the level of albuminuria, MDRD-eGFR, and BP within each treatment group, and hazard ratio obtained from the Cox proportional hazards model adjusted for the baseline level of each factor, country, and gender

OutcomeRosiglitazoneMetforminGlyburideRosiglitazone versus MetforminRosiglitazone versus Glyburide
HR (95% CI)PHR (95% CI)P
Albumin-to-creatinine ratio (ACR) normal ACR (<30 mg/mg) at baseline to albuminuria (ACR ≥30 mg/g)n = 114211561128
        patients, n (%)174 (15.2)217 (18.8)175 (15.5)
        4-year cumulative incidence, % (CI)18.2 (15.7, 20.9)22.5 (19.7, 25.3)20.9 (17.9, 23.9)0.84 (0.68, 1.04)NS0.86 (0.69, 1.08)NS
    albuminuria (ACR ≥30 mg/g) at baseline to normoalbuminurian = 227202187
        patients, n (%)128 (56.4)99 (49.0)99 (52.9)
        4-year cumulative incidence, % (CI)69.5 (62.0, 77.0)63.8 (55.0, 72.5)63.9 (55.1, 72.7)1.27 (0.92, 1.74)NS1.10 (0.80, 1.50)NS
MDRD-eGFR (ml/min per 1.73 m2) normal or high eGFR (≥60 ml/min per 1.73 m2) at baseline to low eGFR (<60 ml/min per 1.73 m2)n = 136413611293
        patients, n (%)93 (6.82)86 (6.32)86 (6.65)
        4-year cumulative incidence, % (CI)8.3 (6.6, 10.0)7.8 (6.1, 9.5)8.4 (6.6, 10.2)1.04 (0.77, 1.40)NS0.91 (0.67, 1.23)NS
    normal eGFR (60 ≤ eGFR ≤ 130 ml/min per 1.73 m2) at baseline to high eGFR (>130 ml/min per 1.73 m2)n = 121212181176
        patients, n (%)271 (22.4)271 (22.3)184 (15.7)
        4-year cumulative incidence, % (CI)28.1 (25.2, 31.0)27.0 (24.1, 29.8)20.4 (17.7, 23.1)0.951 (0.79, 1.14)NS1.44 (1.17, 1.76)0.001
Blood pressure without hypertension at baseline to hypertensionn = 303307290
        patients, n (%)242 (79.9)250 (81.4)241 (83.1)
        4-year cumulative incidence, % (CI)87.0 (82.6, 91.4)89.1 (85.0, 93.2)91.7 (87.9, 95.5)98 (0.80, 1.19)NS0.84 (0.69, 1.03)NS
  • P values adjusted for two comparisons. NS, not significant.